(Q30773458)

26 June 2017

title

Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies (English)

1 reference

26 June 2017

0 references

1 reference

1 reference

10

Ayalew Tefferi

1 reference

26 June 2017

7

Monia Marchetti

1 reference

26 June 2017

Giovanni Barosi

1

1 reference

26 June 2017

Michelle Elliott

2

1 reference

26 June 2017

Letizia Canepa

3

1 reference

26 June 2017

Filippo Ballerini

4

1 reference

26 June 2017

Pier Paolo Piccaluga

5

1 reference

26 June 2017

Giuseppe Visani

6

1 reference

26 June 2017

Gabriele Pozzato

8

1 reference

26 June 2017

Francesca Zorat

9

1 reference

26 June 2017

publication date

1 December 2002

1 reference

26 June 2017

1 reference

26 June 2017

volume

43

1 reference

26 June 2017

issue

12

1 reference

26 June 2017

page(s)

2301-2307

1 reference

Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

Thalidomide in agnogenic and secondary myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

Thalidomide treatment in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

21 January 2018

Thalidomide in cancer

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

Efficacy and safety of thalidomide in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

Myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

[Apoptosis and proliferation in the bone marrow of chronic myeloproliferative disorders--biological and prognostic importance]

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819021000040008

10.1080/1042819021000040008

21 January 2018

Identifiers

DOI

1 reference

26 June 2017

1 reference